Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited, a biotech firm focusing on neurodegenerative diseases, has issued 100,000 new shares following the exercise of listed options, without investor disclosure under specific provisions of the Corporations Act. The company, which is advancing the repurposing of monepantel for ALS treatment, recently reported positive Phase 1 trial results and is preparing for a pivotal study that could lead to FDA approval by 2026.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
